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doi:10.1016/j.jtcvs.2007.04.068bjective: Our objective was to examine the clinical outcomes of aortic valve
eplacement with the Toronto SPV bioprosthesis at 12 years.
ethods: The Toronto SPV was used for aortic valve replacement in 357 patients
rom July 1991 to December 2004. There were 244 men and 113 women with a
ean age of 65 10 years. Aortic stenosis was present in 79% of patients, coronary
rtery disease in 38%, and left ventricular ejection fraction less than 0.40 in 12%.
atients had an annual assessment of valve function using echocardiography. The
ean duration of follow-up was 7.7  3.2 years.
esults: There were 2 operative and 79 late deaths, of which 13 were valve related
nd 25 heart related. Survival at 12 years was 64%  4% and similar to that of the
eneral population matched for age and sex. Forty-nine patients had echocardio-
raphic evidence of bioprosthetic dysfunction. The freedom from structural valve
egeneration at 12 years was 69% 4% for all patients, 52% 8% for patients less
han 65 years of age, and 85% 4% for patients 65 years of age or older (P .002).
ifty patients had redo aortic valve replacement: 45 for structural valve degeneration
nd 5 for endocarditis. The freedom from redo aortic valve replacement at 12 years
as 69%  4%. Cusp tear with consequent aortic insufficiency was the most
ommon cause of structural valve degeneration. At the latest follow-up contact, 226
63%) patients were alive with the Toronto SPV valve in place, and 69% were in
unctional class I, 24% in class II, and 7% in class III.
onclusions: The Toronto SPV bioprosthesis has provided optimal patient survival
nd symptomatic improvement but suboptimal valve durability, particularly in
atients less than 65 years of age. We now use of this valve mostly in older patients
ho have a small aortic annulus.
he Toronto SPV (T-SPV) bioprosthesis (St Jude Medical, Inc, St Paul, Minn)
is a porcine aortic valve fixed with glutaraldehyde at a pressure of 1.5 mm
Hg and with no anticalcification treatment. The valve is designed for im-
lantation in the subcoronary position, and its outer surface is covered with a fine
acron fabric. As with any stentless valve secured in the subcoronary position, the
oronto SPV bioprosthesis relies on the geometry of the recipient’s aortic root for
ts support and function. For this reason, the function of this valve is highly
ependent on the surgeon’s ability to match the valve to the patient’s aortic root and
o implant. Once healed in the aortic root, it functions like a normal aortic valve.
hat is the reason that dilation of the aortic root causes aortic insufficiency (AI) after
ortic valve replacement (AVR) with the Toronto SPV valve, as it does with the
ative aortic valve.1
We have used the Toronto SPV bioprosthesis since July 1991, when it became
vailable under an investigational device exemption. It received approval by the
ood and Drug Administration for clinical use in November 1997. This study is a
eview of our clinical experience with this heart valve.
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A
CDatients and Methods
he review ethics board of our institution approved this study.
rom July 1991 to December 2004, 357 patients underwent AVR
ith the T-SPV at Toronto General Hospital. Table 1 show
linical profile of these patients and Table 2 shows the ope
Abbreviations and Acronyms
AI  aortic insufficiency
AVR  aortic valve replacement
SVD  structural valve degeneration
T-SPV Toronto SPV
ABLE 1. Clinical characteristics of patients
o. of patients 357
ean age  SD (y) 10  65
ange (y) 22–84
ex, No (%)
Male 244 (68)
Female 113 (32)
lectrocardiogram, No. (%)
Sinus rhythm 32 (92)
Atrial fibrillation 19 (5)
Heart block 11 (3)
iming of operation, No, (%)
Elective 297 (83)
Urgent/emergency 60 (17)
YHA functional classification, No. (%)
Class I 20 (5)
Class II 147 (41)
Class III 151 (42)
Class IV 39 (11)
revious AVR, No. (%) 18 (5)
revious infective endocarditis 7 (2)
ssociated diseases, No. (%)
Diabetes mellitus 46 (14)
Peripheral vascular disease 16 (4)
Hypertension 135 (38)
Hyperlipidemia 130 (36)
Severe COPD (FEV1 1.0) 11 (3)
Renal failure 5 (1)
VEF, No. (%)
60% 175 (49)
40%-59% 139 (39)
20%-39% 39 (11)
20% 4 (1)
oronary artery disease, No. (%) 136 (38)
ortic valve lesion, No. (%)
Aortic stenosis 281 (79)
AI 33 (8)
Mixed 43 (12)
scending aortic aneurysm, No. (%) 11 (3)
YHA, New York Heart Association; AVR, aortic valve replacement; COPD,
hronic obstructive pulmonary disease; FEV , forced expiratory volume ini
1
second; LVEF, left ventricular ejection fraction; AI, aortic insufficiency.
0 The Journal of Thoracic and Cardiovascular Surgery ● Januae
e
ata. The first 174 patients were operated during the investiga-
ional device exemption trial and had annual visits to our clinics
or an interview, physical examination and echocardiography to
omply with the Food and Drug Administration guidelines. The
eferring cardiologists followed up the remaining 183 patients and
chocardiography was performed in other institutions. Our re-
earch personnel contacted these 183 patients annually by tele-
hone and collected the echocardiographic reports. The follow-up
anged from 0 to 15 years, mean of 7.7  3.2 years, for a total of
735 patient-years. It was 100% complete.
tatistical Analysis
ll data analyses were performed with SAS 8.1 software (SAS
nstitute, Inc, Cary, NC). Descriptive statistics are reported as the
ean  standard deviation for continuous variables and as fre-
uencies and percentages for categorical variables, unless other-
ise noted. Estimates for long-term survival or freedom from
orbid events were made by the Kaplan-Meier method.
Age- and gender-matched Ontario survival estimates were ob-
ained from the Life Table Template V1.2, a downloadable Excel
preadsheet available from the Association of Public Health Epi-
emiologists in Ontario (www.apheo.ca). This spreadsheet c
ains age- and gender-specific conditional probabilities of surviv-
ng a 5-year age interval. These conditional probabilities were
alculated for a population similar to Canadian 1990. A more
etailed description of the methods can be found in an article by
anuel, Goel, and Williams.2 The survival line depicted in Figu
 represents the averaged conditional probabilities of surviva
ur age- and gender-matched patient sample.
All preoperative variables were entered into Cox regression
nalyses to determine the independent, multivariable predictors of
ate mortality and valve failure. Criterion for retention of variables
ABLE 2. Operative data
ortic valve disease, No. (%)
Degenerative calcification of tricuspid valve 165 (46)
Bicuspid aortic valve 125 (35)
Rheumatic 18 (5)
Prosthetic valve dysfunction 18 (5)
Annuloaortic ectasia 6 (2)
Miscellaneous 25 (7)
ortic valve bioprosthetic size, No. (%)
21 mm 11 (3)
23 mm 45 (13)
25 mm 87 (24)
27 mm 130 (36)
29 mm 82 (23)
ssociated procedures, No. (%)
Coronary artery bypass 136 (32)
Replacement of ascending aorta 11 (3)
Mitral valve repair 4 (1)
ortic crossclamp time, min (mean  SD) 89  25
PB, min (mean  SD) 109  30
D, Standard deviation; CPB, cardiopulmonary bypass.n the model was set at a P value of .05.
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A
CDesults
atient Survival
here were 2 operative and 79 late deaths: 13 valve related,
5 heart related, and 43 resulting from other causes. Patient
urvival at 12 years was 64%  4% and only slightly lower
han that of the general population of Ontario matched for
ge and gender, as seen in Figure 1. The only indepe
ardiac variable predictive of late death was left ventricular
jection fraction less than 40% (risk ratio 2.3, 95% confi-
ence interval 1.3–4.4).
rosthetic Valve Endocarditis
welve patients had prosthetic valve endocarditis, 3 during
he first postoperative year and 8 from 1 to 11 years post-
peratively. Seven patients were treated with antibiotics
lone, and 3 died during or after treatment. Five patients
ere reoperated on during the active phase of endocarditis
nd 1 died. The freedom from prosthetic valve endocarditis
t 1, 5, 10, and 12 years was 99%  0.4%, 98%  0.7%,
6%  1%, and 94%  2%, respectively.
hromboembolic Events
hirty-five patients had thromboembolic events: 21 stroke
nd 14 transient ischemic attacks. Among those who had
troke, 2 died, 13 were left with residual neurologic deficit,
nd 6 recovered completely. The freedom from thrombo-
mbolism at 1, 5, 10, and 12 years was 99%  0.5%,
3%  1%, 88%  2%, and 83%  3%, respectively.
nticoagulation-related Hemorrhage
wenty-one patients were discharged from the hospital on a
egimen of warfarin sodium (Coumadin) because of atrial
brillation. At the time of the last follow-up contact, 19
igure 1. Survival after AVR with Toronto SPV bioprosthesis
solid line) compared with the general population of Ontario
atched for age and sex (dotted line). AVR, Aortic valve
eplacement.atients were receiving warfarin because of either atrial (
The Journal of Thoract
brillation or a previous stroke. Only 1 patient had a major
emorrhagic complication, gastrointestinal bleeding, and
ied.
tructural Valve Degeneration
orty-nine patients had echocardiographic evidence of
tructural valve degeneration (SVD). Severe AI was present
n all but 2 patients who had aortic stenosis. Forty-five
atients with SVD were reoperated on and 4 were not
ecause of comorbid conditions. Among the 45 patients
eoperated on because of SVD, cusps tears were present in
0 patients and gross calcification in 23. Two patients were
eoperated on because of aortic stenosis owing to valve
alcification and pannus in the inflow of the valve. Three
atients had intact valves with severe AI owing to dilation
f the aortic root. In 25 of 49 patients with SVD, the
iameter of the sinotubular junction was 20% or larger than
he diameter of the valve implanted. There were 2 operative
eaths among 45 patients who had redo AVR for SVD. Four
atients with SVD who were not reoperated on died of
alve-related causes. The freedom from SVD at 12 years
as 69%  4% for all patients (Figure 2); for pati
ounger than 65 years of age it was 52%  8%, and for
atients aged 65 years or older it was 85%  4% (P 
001). Cox regression analysis revealed increased age by
-year increments reduced the risk of SVD (risk ratio 0.73,
5% confidence interval 0.6–0.9). The actual freedom from
VD at 12 years was 76% 3% for all patients, 60% 7%
or patients younger than 65 years of age, and 88%  4%
or patients 65 years of age and older (P  .001).
eoperations
ifty patients had redo aortic valve surgery: 45 for SVD and
for prosthetic aortic valve endocarditis. There were 3
perative deaths among 50 patients undergoing reoperation.
he freedom from reoperation at 12 years was 69%  4%
Figure 2. Freedom from structural valve degeneration (SVD).Figure 3).
ic and Cardiovascular Surgery ● Volume 135, Number 1 21
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A
CDemodynamic Analysis
etailed echocardiographic studies in the first 174 patients
evealed that the peak systolic gradient across the T-SPV
ecreased from 12.0 5.6 mm Hg to 7.2 4.8 mm Hg (P
001) and the mean systolic gradient decreased from 5.5 3.1
m Hg to 3.9 2.4 mm Hg (P .01) during the first year of
ollow-up and remained unchanged thereafter during the sub-
equent years. The effective orifice area of the T-SPV in-
reased from 2.0 0.5 cm2 to 2.2 0.6 cm2 (P .02) during
he first year of follow-up and remained unchanged thereafter
or the next decade. No patient had an aortic valve orifice area
ndex of less than 0.85 cm2/m2 after the first year of follow-up.
AI was assessed in all 355 operative survivors The latest
chocardiogram before death or reoperation revealed severe
I in 47 patients, moderate in 6, mild in 37, and none or
rivial in 265. At the latest follow-up contact, 226 patients
ere alive with the T-SPV in place, and 5 had moderate AI,
5 had mild AI, and 196 had none or trace AI. The freedom
rom moderate or severe AI in all patients at 12 years was
8%  6%, as shown in Figure 4.
unctional Status
t the last follow-up contact, 156 (69%) patients were in
ew York Heart Association functional class I, 54 (24%) in
lass II, and 16 (7%) in class III.
iscussion
tentless bioprosthetic aortic valves were reintroduced in 1987
o improve the hemodynamic performance and enhance the
urability of bioprosthetic aortic valves.3 It is generally ac-
epted that stentless bioprosthetic valves have better hemody-
amic performance than stented valves.4,5 There have been
everal randomized clinical trials on the hemodynamic out-
omes of stentless versus stented valves.4-13 Some studies
ound that stentless valves had lower systolic gradients and
arger orifice areas than stented valves whereas other studies
Figure 3. Freedom from reoperation.ound no difference. We believe that the inconsistency in l
2 The Journal of Thoracic and Cardiovascular Surgery ● Januaesults among these trials was due to technical problems re-
ated to implantation of the stentless valves in the subcoronary
osition. In our experience, stentless valves have better hemo-
ynamics than stented valves.14 Moreover, if the technique 
ortic root replacement is used, even better hemodynamics are
btained, and this operative approach can be used as an alter-
ative to patch enlargement of the aortic root to avoid patient–
rosthesis mismatch.15 Implantation of a stentless valve in 
ubcoronary position such as the T-SPV is complicated be-
ause the function of the donor cusps is dependent on the
ecipient’s aortic root. Thus, matching the size of the stentless
alve to the recipient aortic root and securing it in the suban-
ular position has a profound effect on its hemodynamic per-
ormance. For instance, in one of the randomized trials, the
-SPV was compared with the Carpentier–Edwards Perimount
alve (Edwards LifeSciences, Irvine, Calif), and the investiga-
ors found no difference in the hemodynamic parameters or left
entricular mass regression at 1 year postoperatively.9 How-
ver, in that study, the reported mean effective orifice areas for
he T-SPV were approximately 20% smaller than those re-
orted by others,4,5 whereas the effective orifice areas for 
arpentier–Edwards Perimount valve were approximately
0% larger than those reported by others.16,17 Pibarot and
olleagues18 have demonstrated that gradients at rest and -
ng exercise are substantially lower with stentless valves than
ith stented ones. Other investigators have shown that gradi-
nts during exercise increase less among patients with stentless
alves than among similar patients having undergone implan-
ation of mechanical aortic valves.19,20 Lower gradients at re
nd a smaller increase in gradients during exercise suggest that
he prevalence of patient-prosthesis mismatch should be un-
ommon after implantation of a T-SPV valve. Indeed, not a
ingle patient in our study had patient-prosthesis mismatch at 1
ear after surgery as defined as an effective aortic valve area of
igure 4. Freedom from moderate or severe aortic insufficiency
AI).ess than 0.85 cm2/m2.
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A
CDThe hemodynamic advantages of stentless valves should
educe the patients’ operative mortality, particularly in
hose with impaired left ventricular function in whom
atient-prosthesis mismatch has an incremental effect on
perative risk.21 Superior hemodynamic performance ma
lso reduce late mortality, mediated by better left ventricular
emodeling and performance. The survival of patients in this
eries of T-SVP was 64%  4% at 12 years. The survival
as identical to that of the general population of Ontario
atched for age and gender up to 10 years and then declined
lightly, as shown in Figure 1. This drop in survival aft
rst decade is possibly due to increased risk of SVD,
eoperation, and other valve-related events. The survival of
atients with T-SPV bioprostheses during the first decade is
igher than that of patients with stented bioprosthetic valves
f similar age and comorbid conditions in our institutio22
bviously, since the conventional wisdom has been that the
ype of valve has no effect on patient survival, only a large
ontrolled randomized clinical trial on stentless versus
tented valves would settle the contention that stentless
alves confer a survival benefit.
Although patient survival may be higher with T-SPV
han that with stented valves, the reoperation rate for SVD
s higher than with stented valves.22 Currently available
ioprosthetic aortic valves such as the Hancock II
Medtronic, Minneapolis, Minn) appear to be associated
ith lower rates of SVD and reoperation.22 In our hospital
he freedom from SVD at 12 years was approximately 85%
or the Hancock II and 69% for the T-SPV in a patient
opulation of similar age and clinical profile. Even more
orrisome is the fact that at 12 years only 48% of patients
ith T-SPV were free from moderate or severe AI. This
igh rate of SVD with the T-SPV is no doubt related to
ncreased mechanical stress on the cusps of the valve be-
ause of our inability to perfectly match the porcine cusps to
he recipient’s aortic root during implantation and also
ecause of late dilation of the sinotubular junction.1,23,24
ctually, in one half of all patients who had severe AI, the
iameter of the sinotubular junction had increased by 20%
r more than the diameter of the valve implanted, suggest-
ng that dilation of the sinotubular junction was a common
ause of AI in this series. In a previous study on this topic,
e1 proposed to stabilize the sinotubular junction wit
trip of Dacron fabric after implantation of the T-SPV. The
ffect of that maneuver will not be known for several more
ears because of inadequate length of follow-up.
In this study, we defined SVD as recommended in the
uidelines to report outcomes on heart valve surgery. Of 49
atients with echocardiographic evidence of severe valve
ysfunction, 47 had AI and 2 had stenosis, but at surgery, 3
atients with severe AI had valves without SVD, and the
alves were incompetent because of dilation of the sinotu-
ular junction. Further complicating the issue of SVD in
The Journal of Thorace
atients with stentless valves is moderate and mild AI. If
here is no echocardiographic evidence of cusp calcification,
hese degrees of valve dysfunction are not included in SVD.
his issue should be included in future guidelines on re-
orting outcomes on stentless valves.
Reoperations in patients who had AVR with the T-SPV
alve are more complicated than those with stented valves.
lthough there were only 3 operative deaths among 50
eoperations in this series, more than one half of the patients
equired complex reconstruction of the aortic root because
he aortic sinuses and/or annulus and coronary artery ori-
ces were damaged during removal of the valve.
In summary, AVR with T-SPV results in optimal patient
urvival, hemodynamic features, and symptomatic improve-
ent in this series but suboptimal valve durability, partic-
larly in patients less than 65 years of age. Reoperation for
ate valve failure is complex and often necessitates aortic
oot replacement and patch repair of the coronary artery
rifices. For these reasons, we now use this valve mostly in
lder patients who have a small aortic annulus and whom
e do not expect to outlive the valve.
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iscussion
r Arvind Koshal (Edmonton, Alberta, Canada). Thank you very
uch, Dr David, for an excellent presentation. This is an excellent
xample to all of us of how you took a product from the initial
evelopment stage, brought it into the market, and are now pro-
iding us with 100% follow-up on these 357 patients. You should
e congratulated for doing that and giving us a lot of information.
It is interesting that the survival has been good despite a
urability issue that we have seen with tissue valves in the past.
he difference, though, in using stented valves with poor durabil-
ty was that at the time of reoperation, the reoperation was not that
echnically complicated. What were the technical problems on
eoperation in these patients who have a more complex way of
nsertion and also where coronary ostia and sinuses are involved?hat kind of valve or conduit do you use at that stage? I
4 The Journal of Thoracic and Cardiovascular Surgery ● JanuaDr David. The experience is largely personal. We have oper-
ted on 50 patients, and 28 required aortic root replacement be-
ause in attempting to remove the valve we damaged the aortic
inuses and/or aortic arch annulus. The operative mortality for
lective reoperation for failed stentless valves is twice as high as
or bioprostheses.
Dr Koshal. What kind of valve did you use at the second
peration?
Dr David. Surprisingly, most patients wanted a bioprosthesis
gain.
Dr Koshal. The other interesting thing in your series is that you
ave a significant percentage of bicuspid aortic valves. As you
now, with bicuspid valves the aorta is more prone to degenerative
hanges. Did you find a difference in the durability in the bicuspid
ersus the tricuspid valves that were replaced?
Dr David. That is an important question. Patients with bicuspid
ortic valves eventually had aortic dilation, and because this valve
unction is dependent on the aortic root, if the aorta dilates the
alve becomes incompetent. This was the case, unfortunately, but
icuspid aortic valve was not a predictor of late failure. Dilatation
f the aorta was. Unfortunately, the literature suggests that the
orta dilates as we age. In the age group of 50 to 80 years, if the
orta increases from 25 to 30 mm in diameter to 35 mm or so, this
alve is rendered incompetent. I learned this only in 1998 and I
tarted banding it, but we do not have long enough follow-up on
hose patients. Clearly, dilatation of the aorta was the most com-
on mode of failure in these patients.
Dr Koshal. Finally, what are you going to do with this valve
ow? How many of these do you use in your practice and what
ave you changed to?
Dr David. I continue using it but I do not use it in younger
atients anymore. The enthusiasm was so great 18 years ago when
t was first developed. We thought it was going to take over the use
f homografts because it is relatively easy to implant and I thought
t was going to be more durable. We limit it to older patients, over
5 or 70 years. In those, failure is uncommon. Hemodynamically,
t is an outstanding valve.
Dr John Brown (Indianapolis, Ind). Do you have any com-
arison of the Toronto valve with the other stentless valves on the
arket to see whether they are showing the same problems that the
oronto valve has?
Dr David. We do, Dr Brown. We have followed up most
atients who had valve surgery with biological and bioprosthetic
alves. Compared with the Hancock II, this valve is not as durable,
ot by much though. At 10 years there is a 10% difference and at
2 years a 12% difference for all comers. However, the survival at
2 years is 20% better for the stentless valve. I am not saying that
f I need an AVR, I am going to have a stentless valve because I
m likely to live longer than the durability of this valve. The
eneficial effect of better hemodynamics likely is not apparent in
he first year or two. It might take a decade or more to become
pparent. I firmly believe that if a patient comes for AVR, the
urgeon should resolve the hemodynamic burden that the native
ortic valve disease caused. This valve is very close to it in elderly
atients, and that is why I continue using Ross in younger patients.
think it is an outstanding operation in properly selected patients.t restores the outflow tract to normality.
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